// App-Quantinova.ai

2158 : Pharmacologic, pharmacodynamic action of MELK kinase inhibitor OTS167 in cancer cells

Researchers

Presenter

  • Suyoun Chung

Principal Investigators

  • Kyoko Kijima

  • Yosuke Harada

  • Naofumi Takamatsu

  • Takashi Miyamoto

  • Yo Matsuo

  • Yusuke Nakamura

Medical Centers

  • OncoTherapy Science, Inc., Kanagawa, Japan

  • The University of Chicago Medical Center, Chicago, IL

Locations

  • United States

  • Japan

Companies

  • OncoTherapy Science,

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Maternal Embryonic Leucine Zipper Kinase

Drug/Treatment

  • OTS167

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved